Development and validation of a rapid and sensitive UPLC–MS/MS assay for the quantification of tofacitinib in human plasma

• Published in: Biomedical chromatography Vol. 33; no. 4; pp. e4458 - n/a
• Main Authors: Bharwad, Kirtikumar D., Shah, Priyanka A., Shrivastav, Pranav S., Singhal, Puran
• Format: Journal Article
• Language: English
• Published: England 01.04.2019
• Subjects: human plasma; liquid–liquid extraction; pharmacokinetic study; tofacitinib; tofacitinib‐13C3 15 N; UPLC–MS/MS; pharmacokinetic study; tofacitinib-13C3 15 N; UPLC-MS/MS; liquid-liquid extraction; human plasma; tofacitinib
• ISSN: 0269-3879; 1099-0801; 1099-0801
• DOI: 10.1002/bmc.4458

A highly sensitive, selective and rapid ultra‐performance liquid chromatography–tandem mass spectrometry method has been developed for the quantification of a Janus kinase (JAK) inhibitor, tofacitinib (TOF). The assay employed liquid–liquid extraction with methyl‐tert butyl ether to extract tofacitinib and tofacitinib‐13C3 15 N (as internal standard) from human plasma. The samples were analyzed on a UPLC BEH C18 (50 × 2.1 mm, 1.7 μm) column using acetonitrile and 10.0 mm ammonium acetate, pH 4.5 (75:25, v/v) as the mobile phase within 1.4 min. The precursor/product ion transitions were monitored at m/z 313.3/149.2 and 317.4/149.2 for tofacitinib and tofacitinib‐13C3 15 N, respectively, in the positive electrospray ionization mode. The calibration curves were linear (r2 ≥ 0.9978) across the concentration range of 0.05–100 ng/mL. The mean extraction recovery of tofacitinib across quality controls was 98.6%. The intra‐ and inter‐batch precision (CV) and accuracy ranged from 2.1–5.1 and 96.2–103.1%, respectively. All validation results complied well with the current guidelines. The method is amenable to high sample throughput and was applied to determine TOF plasma concentration in a pharmacokinetic study with 12 healthy Indian subjects after oral administration of 5 mg tablets.